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Abstract: 
Cutaneous T cell lymphoma (CTCL) is a group of malignancies derived from 
skin-homing T cells. Mycosis fungoides (MF) and Sézary syndrome (SS), are the 
most common CTCL variants. In recent years, the genetic landscape of SS/MF  
has been characterized using genome-wide next-generation sequencing (NGS) 
approaches. These studies have revealed that genes subjected to oncogenic 
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mutations take part in cell cycle regulation, chromatin modification, JAK-STAT 
signaling, TCR/NF-κB signaling and MAPK signaling, which suggests that 
deregulation of these cellular processes underlie lymphomagenesis. These studies 
provide the groundwork for functional and clinical studies that will lead to better 
risk assessment and more effective therapeutic approach in CTCL patients. 
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Introduction 
Cutaneous T cell lymphomas (CTCLs) are malignancies derived from skin-
homing T cells. Mycosis fungoides (MF), the most common CTCL, typically 
presents with patches and plaques especially on sun-protected areas of the skin. 
The disease has an indolent clinical course with slow progression from patches to 
more infiltrated plaques and eventually to tumors. In a minority of patients, 
extracutaneous localization develops in later stages of the disease. The prognosis 
of MF patients depends on stage, in particular, the type and extent of skin lesions 
and presence of extracutaneous disease.1 While patients with early stages of 
disease have an excellent prognosis, the 10-year disease-specific survival of 
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patients with tumor stage disease and patients with histologically documented 
lymph node involvement is 42% and 20%, respectively.2 
Sézary syndrome (SS), on the contrary, is a leukemic CTCL variant. SS presents 
with pruritic erythroderma, lymphadenopathy and presence of tumor cells (known 
as Sézary cells) in skin, lymph nodes and peripheral blood. Patients with SS have 
a poor prognosis, with a 5-year survival of 30%.1,2   
The genetic alterations in CTCL, in particular SS, and to a lesser extent MF, have 
been studied using cytogenetic and array-based methods. These studies identified 
extensive genetic instability with complex karyotypes but no highly recurrent 
translocations. In contrast, recurrent copy number alteration (CNA) were 
identified including deletion of CDKN2A in both SS and MF, deletion of RB1 in 
SS, and gain of MYC in SS.3,4  
In recent years, genome-wide studies using next-generation sequencing (NGS) 
have provided a more comprehensive picture of the genetic landscape of CTCL. 
Most of these studies have focused exclusively on SS (7 of 11),5-11 while some 
others included MF samples together with SS samples (4 of 11),12-15 and one 
study focused on MF only (Table 1).16 Taken together, these studies include ~8 
times more SS samples than MF samples, making the reported findings mostly a 
molecular representation of SS. Recently, all CTCL samples with publicly 
available sequencing data have been re-analyzed applying uniform methods and 
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metrics to generate a more representative overview of point mutation frequencies 
in putative driver genes.17 This article summarizes the most relevant findings in 
CTCL genetics derived from NGS studies and examines their therapeutic 
implications. 
 
Next Generation Sequencing 
 NGS refers to a group of high-throughput technologies used to determine 
the order of nucleotides within nucleic acid molecules (i.e. DNA and RNA). In 
cancer research, NGS is particularly suitable for the discovery of different types 
of genetic alterations ranging from pathogenic single nucleotide substitutions to 
large chromosomal aberrations in cancer genomes. The terms whole-genome 
sequencing (WGS), whole-exome sequencing (WES) and targeted sequencing 
(TS) refer to NGS approaches that characterize the entire genome, the complete 
set of coding genes (known as exome, ˂2%  of the genome) or a defined group of 
individual genes, respectively.18,19 Another NGS application called RNA 
sequencing (RNA-seq) is used to characterize the collection of expressed genes in 
the cell known as the transcriptome, which makes possible the identification of 
abnormal gene expression patterns in malignancies when compared to healthy 
controls, and the detection of expressed gene fusions derived from chromosomal 
rearrangements.18 The large majority of studies reviewed in this article have made 
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use of WES and/or TS to investigate SS/MF, whereas a minority of them opted 
for WGS or RNA-seq.           
 
Discovery of molecular alterations in SS/MF using NGS 
NGS data derived from the genome or transcriptome are analyzed using a variety 
of bioinformatic tools that allow the identification of genetic alterations or 
abnormal gene expression, respectively. In the case of SS/MF, these analyses 
have uncovered a distinctive mutational landscape and revealed that genes 
affected by point mutations and CNAs cluster mainly into five cellular processes: 
cell cycle regulation, chromatin modification, JAK-STAT signaling, TCR/NF-κB 
signaling and MAPK signaling (Figure 1). An overview of these findings is 
presented below.  
 
The genomic landscape of SS/MF 
The somatic mutation rate in SS (i.e. average, 3.85 mutations/Mb) is similar to 
mutation rates observed in adult solid tumors.6 The majority of somatic single 
nucleotide substitutions observed in SS/MF are C˃T transitions (40%-75%),6,16 
which are much less common in other hematological cancers.6 This mutational 
signature is regarded as caused by UV light exposure when occurring at NpCpG 
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sites,6,11,16 or aging when occurring at NpCpC sites. In SS, both aging (43%) and 
UV radiation (30%) contribute to C˃T transitions.6,20 At present it is unclear 
whether exposure to UV light plays a causative role in the onset of the disease.  
The fact that oncogenic alterations in SS much more frequently result from CNAs 
rather than single nucleotide substitutions suggests that the former may play an 
important role in SS lymphomagenesis.11 Choi and colleagues reported complex 
genomic rearrangements associated with deletion of tumor suppressors in SS, 
suggesting that phenomena such as chromothripsis or chromoplexy could be key 
events in the development of CTCL.11 These authors proposed that deregulation 
of a group of DNA-cutting enzymes encoded by recombination activated genes 
(RAGs) may be implicated in the characteristic genomic instability of SS.11 
 
Cell cycle and DNA repair 
The cell cycle is a series of systematic events that regulate the correct division of 
a cell into two daughter cells. Although cyclins and cyclin-dependent kinases 
(CDKs) govern cell cycle progression, multiple other proteins participate 
indirectly in the regulation of the cell cycle.21 For instance, ATM, RB1, TP53 and 
CDK inhibitors (CKIs) act on different signaling levels to ultimately induce cell 
cycle arrest in response to DNA damage. In SS, CKIs encoded by CDKN1A and 
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CDKN2A, are deleted in 11% and 40% of cases, respectively.6,11 Deletions of 
ATM (30%), RB1 (39%) and TP53 (93%) are frequent as well.6,11   
 
JAK-STAT signaling 
Cytokines are small secreted proteins that mediate communication between cells. 
Receptors on T cells bind specific cytokines, become activated, and elicit changes 
in gene expression through intracellular signaling pathways. The JAK-STAT 
pathway is central to cytokine stimulation in T cells.22 Cytokine-bound receptors 
activate JAK kinases, which then activate STAT proteins. Activated STAT 
proteins dimerize and translocate to the nucleus where they induce expression of 
genes responsible for T-cell proliferation, differentiation and apoptosis.22 
Point mutations either predicted or confirmed to be gain-of-function are reported 
in JAK1 (0.9% of cases), JAK3 (2.7%), STAT3 (0.9%) and STAT5B (3.6%).17 
Hyperactive JAK and STAT proteins often result from structural changes in their 
functional domains (Figure 1). For instance, amino acid substitutions in the 
pseudokinase domain of JAK proteins enhance their tyrosine kinase activity while 
changes in the SH2 domain of STAT proteins are predicted to enhance 
dimerization. In addition, copy number gains of JAK2 (13% of cases), STAT3 
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(60%) and STAT5B (60%) are frequent and have been shown to correlate with 
increased expression (Figure 1).17 
The existence of FDA-approved JAK inhibitors such as Tofacitinib and 
Ruxolitinib makes the idea of targeting malignant T cells driven by hyperactive 
JAK kinases attractive. In two separate NGS studies, the authors demonstrated 
that CTCL cell lines bearing gain-of-function point mutations in JAK3 are 
sensitive to these compounds, opening the possibility for their potential use in 
CTCL patients carrying JAK mutations.15,16     
 
MAPK signaling 
Similarly to the JAK-STAT pathway, the MAPK pathway propagates towards the 
nucleus extracellular signals received through cytokine receptors. These signals 
elicit cellular processes such as growth, proliferation and apoptosis.23 Subsets of 
SS/MF patients carry established gain-of-function mutations (˂1%) in several 
members of this pathway such as KRAS, NRAS, BRAF, MAP2K1 and MAPK1 
(Figure 1).17  
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TCR/NF-κB signaling 
Initiation of the adaptive immune response against pathogens relies on the 
activation of T cells capable of recognizing foreign antigens. Upon binding 
between the T-cell receptor (TCR) and its cognate antigen, a series of signaling 
events lead to the expression of genes that promote T-cell survival, proliferation 
and differentiation.24 Activated T cells then orchestrate multiple immunological 
events directed at clearing the pathogen from the body.  
In CTCLs, hyperactive TCR signaling might drive uncontrolled proliferation of 
malignant T cells. Genetic alterations reported in SS/MF target a variety of 
components of the TCR pathway.6,11,13,15 CD28 is a co-stimulatory molecule of 
the TCR complex, which by engaging ligand B7 (CD80 and CD86) on antigen 
presenting cells (APCs), co-signals for T-cell activation.24 Increased affinity of 
CD28 for B7 due to amino acid substitutions or gene fusions results in augmented 
TCR signaling. Point mutations in CD28 occur in 3.6% of cases while in-frame 
gene fusions (i.e. CD28-ICOS and CD28-CTLA4) have been observed in a small 
number of cases (Figure 1).6,7,13,17  
Downstream to TCR activation, phospholipase PLCγ1 catalyzes the production of 
second messengers (i.e. DAG and IP3), which in turn, activate downstream 
kinases.24 Point mutations in the catalytic core of PLCγ1 (10% of cases) and copy 
number gains (5%) increase second messenger production which enhance antigen-
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dependent T-cell activation (Figure 1).12,17 Furthermore, point mutations in DAG-
activated kinases PRKCB and PRKCQ (˂1% of cases) and amplification of the 
latter (30%) may contribute to TCR signaling deregulation (Figure 1).17 However, 
the functional relevance of these alterations remains uncertain.   
Gene expression changes triggered by TCR activation are effected through 
canonical NF-κB signaling and other downstream pathways.24 CARD11 encodes a 
scaffold protein needed for the activation of transcription factor complex NF-κB. 
In SS/MF, point mutations (5.4% of cases) and copy number gains (23%) 
involving CARD11 lead to increased NF-κB activation (Figure 1).13,15,17 In 
addition, recurrent deletions (2.5% of cases) of the C-terminal auto-inhibitory IκB 
domain of NFKB2 are expected to render it constitutively active.13,17  
Besides the TCR complex, other receptors can also elicit canonical NF-κB 
signaling in CTCL. Membrane receptor TNFR2 (encoded by TNFRSF1B) initiates 
NF-κB signaling upon binding to ligand TNFɑ. Reported activating point 
mutations in TNFRSF1B enable constitutive NF-κB signaling without the need of 
a ligand.13 Overall, point mutations and amplifications involving TNFRSF1B are 
reported in 2.2% and 2.5% of cases, respectively .13,17 In addition, TNFAIP3, 
which encodes an inhibitor of TNFɑ-induced NF-κB signaling, is deleted in 25% 
of SS cases (Figure 1).   
11 
 
In line with these studies, pharmacological inhibition of complex NF-κB 
decreased its DNA binding ability and induced cell death of SS cells in vitro.25,26 
In a phase II study the safety and efficacy of the NF-κB inhibitor bortezomib were 
evaluated in 10 MF patients.27 The overall response rate (ORR) for MF was 70 % 
and the complete response rate (CRR) was 10 % suggesting the potential 
usefulness of NF-κB inhibitors in CTCL treatment.27 
 
Chromatin modification 
Chromatin consists of genomic DNA and associated proteins. Histone proteins, 
the main structural components of chromatin, form a protein core around which 
DNA winds called the nucleosome. Histones not only play roles in the packaging, 
replication, and repair of DNA, but also regulate gene expression.28,29 Both DNA 
and histones are subjected to chemical (known as epigenetic) modifications that 
direct changes in chromatin architecture. DNA methylation, histone methylation, 
and histone acetylation are epigenetic modifications with established effects on 
gene expression.28,29  
Proteins that chemically alter chromatin, named epigenetic regulators, can be 
divided into three categories: writers, erasers and readers. Writers are enzymes 
that add epigenetic marks to either DNA or histones, erasers reverse the action of 
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writers, and readers interpret epigenetic marks to elicit downstream signals.28,29 
Epigenetic regulators are frequently mutated in CTCLs, particularly, SS.  
 
DNA methylation 
In normal cells, widespread DNA methylation maintains chromosomal stability 
whereas low methylation at gene promoters allows transcription. In cancer, this 
methylation pattern is typically inverted promoting genome instability and 
transcriptional misregulation. Loss-of-function alterations in DNA 
methyltransferases (DNMT) can lead to global hypo-methylation.30 In SS, DNA 
methyltransferase DNMT3A is frequently deleted (38%) and mutated (4%) 
(Figure 1). Opposing DNMTs, TET enzymes demethylate DNA by oxidizing 
methylated cytosine residues in successive enzymatic steps. TET2 is often 
inactivated in hematological malignancies, though, its role in cancer development 
is not clear.31 In SS, TET2 mutations (3.6% of cases) and deletions (2.5%) are 
reported too (Figure 1). In line with these results, it was shown that SS cells are 
characterized by widespread changes in DNA methylation suggesting that SS 
could be amenable to treatment with demethylating agents.32       
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Histone methylation  
Histone methyltransferases (HMTs) are enzymes that add one, two or three 
methyl groups to specific lysine or arginine residues on histones, while histone 
demethylases (HDMs) remove them. Histone methylation can signal either for 
gene activation or repression depending on the location of the epigenetic mark.29 
Aberrant methylation patterns on histones are extensively observed in 
malignancies and are likely to be a consequence of damaging mutations in HMTs 
and HDMs.29 In SS, two histone demethylases, KMT2C and KMT2D, are mutated 
in 2.2% and 3.1% of cases, respectively; while a third enzyme, SETDB2, is 
deleted in 28% of cases. In addition, mutations in histone demethylase KDM6A 
are also seen in 1.3% of SS cases (Figure 1).  
 
Histone Acetylation 
Acetylation of lysine residues on histones activates gene expression by inducing 
chromatin relaxation. Acetyl groups neutralize the positive charge of lysine 
residues which decreases the attraction between the nucleosome and the 
negatively charged DNA. The addition of acetyl groups is mediated by histone 
acetyltransferases (HATs). In SS, histone acetyltransferase CREBBP, can be 
mutated (3.1% of cases) or deleted (2.5%). By contrast, removal of acetyl groups 
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is carried out by histone deacetylases (HDACs). Deletions involving histone 
deacetylase NCOR1 are frequent in SS/MF (80%) while point mutations are less 
common (3.1%) (Figure 1). Another histone deacetylase, BCOR, is mutated in 
2.7% of cases.17 Finally, adapter protein TRRAP which is part of various 
multiprotein complexes with HAT activity, is amplified in 10% of cases and 
mutated in 4.9% of cases (Figure 1).17  
Two systemic HDAC inhibitors (HDACis) are FDA-approved for the treatment of 
CTCL, including romidepsin (class I-specific HDACi) and vorinostat (pan-
HDACi). Trials with (novel) HDACis as single agents or in combinations are now 
underway in diverse cancer types, including hematologic and solid tumors, but 
have not yet reached the clinic.33 However, insight in the mechanisms through 
which different HDACis suppress tumors is limited and elucidation how 
epigenetic drugs exert their anti-cancer effect will be crucial to further develop 
and optimize these therapies. 
 
Chromatin remodeling 
Chromatin remodelers are multiprotein complexes that change the degree of 
chromatin compaction and nucleosome position in response to upstream 
epigenetic signals. These changes in chromatin architecture regulate gene 
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expression. Genetic alterations involving members of the SWI/SNF family of 
chromatin remodelers are common in human cancers.34 For instance, ARID1A and 
SMARCB1 are frequently mutated in gastric and rhabdoid tumors, respectively.34 
In SS, deletion of ARID1A (58%), ARID5B (29%) and SMARCC1 (21%) are the 
most frequent alterations involving chromatin remodeling genes.9,17 Furthermore, 
ARID1A deletions have been shown to correlate with lower expression levels in 
SS.11 Similarly, point mutations in chromatin remodeling genes ARID2 and 
SMARCB1 have been reported in subsets of MF patients.16 
 
Conclusion/Outlook 
The combined results from recent NGS studies have uncovered extensive genetic 
changes in SS/MF, including recurrent CNAs and point mutations that affect key 
pathways that likely are of critical importance in driving the disease. In the 
forthcoming years, it will be essential to integrate genetic studies with 
transcriptional data, and develop pre-clinical models to determine the functional 
consequences of the identified genetic alterations. These studies will guide the 
development of new therapeutic strategies including the targeting of frequently 
affected cellular processes, such as NF-κB and JAK-STAT signaling, and 
chromatin  regulation. Prospective studies on large numbers of CTCL patients, 
such as the Cutaneous Lymphoma International Consortium, will be essential to 
16 
 
correlate specific genetic alterations with clinical course and response to therapy. 
It is hoped that ultimately these studies will lead to an individualized risk 
assessment and effective therapeutic approach. 
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Authors Journal Year CTCL variant  
(# of samples) 
WGS WES TS RNA-seq 
Lee et al. Blood 2012 SS (3), MF (24)    27 
Sekulic et al. Mol Genet Genomic Med 2014 SS (1) 1   1 
Vaqué et al. Blood 2014 SS (4), MF (7)   11  
Choi et al. Nat Genet 2015 SS (40) 2 40   
McGirt et al. Blood 2015 MF (30) 5  25  
Ungewickell et al. Nat Genet 2015 SS (32), MF (41)  11 73  
Kiel et al. Nat Comm 2015 SS (66) 6 66   
Da Silva Almeida et al.  Nat Genet 2015 SS (25), MF  (8), 
Other CTCLs (9)  
 42   
Wang et al. Nat Genet 2015 SS (37)  37 37 32 
Prasad et al. J Invest Dermatol 2016 SS (12)  12  10 
Woollard et al. Blood 2016 SS (101)  10 101  
Izykowska et al.  Oncotarget 2017 SS (9) 9   9 
Table 1. NGS studies on CTCL. The majority of published studies used WES to 
characterize the mutational landscape of SS/MF genomes. CTCL, cutaneous T 
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cell lymphoma. SS, Sézary syndrome. MF, mycosis fungoides. WGS, whole-
genome sequencing. WES, whole-exome sequencing. TS, targeted sequencing. 
RNA-seq, RNA sequencing. 
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